. 2017 Aug 17;9(2):321–331. doi: 10.1111/jdi.12711

Table 3.

Safety and adverse effects of alpha‐glucosidase inhibitor treatment compared with the placebo in Asian and non‐Asian patients with type 2 diabetes

Variables	Asian					Non‐Asian					P‐value of difference
Variables	No. studies	No. participants	No. adverse effects	OR	95% CI	No. studies	No. participants	No. adverse effects	OR	95% CI	P‐value of difference
Hypoglycemia
Mono	–	–	–	–	–	5	293/296	14/12	1.15	0.52, 2.58	–
Add‐on	4	245/238	69/58	1.23	0.80, 1.89	7	657/674	69/41	1.96^a	1.27, 3.03	0.407
Total	5	407/318	71/58	1.25	0.82, 1.91	12	950/970	83/53	1.75^a	1.19, 2.55	0.278
Gastrointestinal events
Flatulence	8	472/420	164/74	3.24^a	2.29, 4.58	19	1,656/1,393	1,047/313	6.93^a	5.81, 8.27	0.083
Diarrhea	6	355/304	46/15	3.25^a	1.78, 5.94	17	1,572/1,309	595/155	4.53^a	3.70, 5.55	0.013^a
Abdominal pain	2	77/76	5/1	3.87	0.61, 24.36	11	849/778	107/36	2.83^a	1.91, 4.20	0.453
Constipation	2	99/55	7/0	9.00	0.50, 160.65	4	291/308	29/22	1.45	0.81, 2.59	0.819

P‐value <0.05.